Incannex’s IHL-42X Wins Top Drug Development Award after Phase 2 AHI Drop
IXHL•Incannex Healthcare’s IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide, won the Best New Technology Solution for Drug Development award in the 10th MedTech Breakthrough Awards. In its Phase 2 RePOSA trial, IHL-42X achieved statistically significant reductions in apnea-hypopnea index alongside improved oxygenation, sleep quality and fatigue.
1. Award Recognition
Incannex Healthcare was named winner of the Best New Technology Solution for Drug Development award at the 10th annual MedTech Breakthrough Awards, highlighting its leadership in next-generation therapeutic innovation and raising the company’s profile in the biopharmaceutical sector.
2. Phase 2 RePOSA Trial Results
The Phase 2 RePOSA trial demonstrated that IHL-42X produced statistically significant reductions in apnea-hypopnea index (AHI), with concurrent improvements in blood oxygenation levels, overall sleep quality metrics and patient-reported fatigue outcomes, underscoring its clinical efficacy in obstructive sleep apnea.
3. Drug Mechanism and Innovation
IHL-42X combines dronabinol and acetazolamide—two established agents with complementary mechanisms—to target ventilatory control instability and upper airway dysfunction, representing a novel oral fixed-dose approach designed to address physiological drivers of obstructive sleep apnea.
4. Strategic Outlook and Next Steps
This external validation arrives as Incannex prepares to advance IHL-42X into late-stage development while exploring strategic partnerships and potential regulatory pathways, reinforcing its strategy to commercialize differentiated combination therapies for high-impact indications.
